Stephen L. Nishimura

University of California, San Francisco — United States

Medicine · Health Sciences

49h-index8.4kcitations122works7.22yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell Adhesion Molecules Research(38), Immunotherapy and Immune Responses(18), Cancer Immunotherapy and Biomarkers(12), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(11), TGF-β signaling in diseases(11)

Publications122 total

Type 1 and type 2 dendritic cell subsets cooperate to maintain intestinal immune tolerance via integrin αvβ8-mediated TGF-β activation

2026Open Access

Latent-TGF-β has a domain swapped architecture

Nature Communications·2025Open Access

582 First-in-human phase 1/2 study of the integrin αvβ8-blocking antibody CRB-601 in patients with solid tumors

Regular and Young Investigator Award Abstracts·2025Open Access

Latent-TGF-β has a domain swapped architecture

2024Open Access

Dynamic allostery drives autocrine and paracrine TGF-β signaling

36 cited

Cell·2024· 36 citedOpen Access

833 CRB-601, a selective integrin αvβ8-blocking antibody, prevents TGFβ activation, promotes immune cell remodeling, and exhibits potent antitumor activity

Regular and Young Investigator Award Abstracts·2023Open Access

Supplementary Table 3 from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection

2023Open Access

Supplementary Table 1 from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection

2023Open Access

Supplementary Table 1 from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection

2023Open Access

Supplementary Table 2 from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection

2023Open Access

Supplementary Table 2 from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection

2023Open Access

Data from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection

2023Open Access

Data from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection

2023Open Access

Supplementary Table 3 from Reprogramming Tumor-Infiltrating Dendritic Cells for CD103+CD8+ Mucosal T-cell Differentiation and Breast Cancer Rejection

2023Open Access

Supplementary Table S1 from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies

2023Open Access

Supplementary Table S1 from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies

2023Open Access

Data from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies

2023Open Access

Supplementary Table S2 from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies

2023Open Access

Data from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies

2023Open Access

Supplementary Fig. S1 from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies

2023Open Access

page 1 of 7Next →

Frequent Co-authors

Jun Araya(12), Jody L. Baron(11), Stephanie Cambier(10), Dean Sheppard(9), Robert Pytela(9), Saburo Ito(9), Shunsuke Minagawa(8), V. Courtney Broaddus(7), Naoki Takasaka(6), Hiromichi Hara(6), Makoto Odaka(6), Toshiaki Morikawa(6), Katsutoshi Nakayama(6), Kazuyoshi Kuwano(6), David M. Jablons(6), Haruhiko Yanagisawa(5), Makoto Kawaishi(5), Takanori Numata(5), Amanda Goodsell(5), James D. Marks(5)